Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ATRS

Antares Pharma (ATRS) Stock Price, News & Analysis

Antares Pharma logo

About Antares Pharma Stock (NASDAQ:ATRS)

Advanced Chart

Key Stats

Today's Range
$5.59
$5.59
50-Day Range
$5.59
$5.59
52-Week Range
$3.11
$5.60
Volume
6 shs
Average Volume
3.29 million shs
Market Capitalization
$955.06 million
P/E Ratio
23.29
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Antares Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

ATRS MarketRank™: 

Antares Pharma scored higher than 38% of companies evaluated by MarketBeat, and ranked 737th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Antares Pharma.

  • Earnings Growth

    Earnings for Antares Pharma are expected to grow by 175.00% in the coming year, from $0.08 to $0.22 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Antares Pharma is 23.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.85.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Antares Pharma is 23.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.26.

  • Price to Book Value per Share Ratio

    Antares Pharma has a P/B Ratio of 5.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ATRS.
  • Dividend Yield

    Antares Pharma does not currently pay a dividend.

  • Dividend Growth

    Antares Pharma does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ATRS.
  • Search Interest

    1 people have searched for ATRS on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Antares Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.90% of the stock of Antares Pharma is held by insiders.

  • Percentage Held by Institutions

    50.41% of the stock of Antares Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Antares Pharma's insider trading history.
Receive ATRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antares Pharma and its competitors with MarketBeat's FREE daily newsletter.

ATRS Stock News Headlines

Best Healthcare Penny Stocks
Antares Vision SpA AV
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
Antares Vision Share Price (AV.MI)
Antares Reaches New 52-Week High (AIS)
Antares Vision SpA (ANV)
COP Syringes Market Competitive Situation By 2030
See More Headlines

ATRS Stock Analysis - Frequently Asked Questions

Antares Pharma, Inc. (NASDAQ:ATRS) released its quarterly earnings results on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, hitting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate of $48.52 million. Antares Pharma had a net margin of 21.90% and a trailing twelve-month return on equity of 7.43%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), NVIDIA (NVDA), Micron Technology (MU), Meta Platforms (META) and Prospect Capital (PSEC).

Company Calendar

Last Earnings
11/04/2021
Today
7/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:ATRS
CIK
1016169
Employees
201
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
$0.24
Trailing P/E Ratio
23.29
Forward P/E Ratio
69.88
P/E Growth
N/A
Net Income
$46.29 million
Net Margins
21.90%
Pretax Margin
29.84%
Return on Equity
7.43%
Return on Assets
4.92%

Debt

Debt-to-Equity Ratio
0.10
Current Ratio
3.08
Quick Ratio
2.87

Sales & Book Value

Annual Sales
$183.98 million
Price / Sales
5.19
Cash Flow
$0.13 per share
Price / Cash Flow
43.89
Book Value
$1.03 per share
Price / Book
5.43

Miscellaneous

Outstanding Shares
170,852,000
Free Float
160,772,000
Market Cap
$955.06 million
Optionable
Optionable
Beta
1.15

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ATRS) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners